Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.35 |
| ▸ | DPP4 | P27487 | 9/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 9/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 9/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2993204 | 1.00 | ATM (0.41) | ATMPOLBL3MBTL1PIK3CDDPP4 | |
| SCHEMBL3316717 | 1.00 | ATM (0.41) | ATMPOLBL3MBTL1PIK3CDDPP4 | |
| SCHEMBL21801954 | 1.00 | ATM (0.41) | ATMPOLBL3MBTL1PIK3CDDPP4 | |
| SCHEMBL2563460 | 1.00 | ATM (0.41) | ATMPOLBL3MBTL1PIK3CDDPP4 | |
| SCHEMBL23119911 | 0.82 | ATM (0.40) | ATMPIK3CDDPP4DPP8DPP9 | |
| SCHEMBL20554147 | 0.82 | ATM (0.40) | ATMPIK3CDDPP4DPP8DPP9 | |
| SCHEMBL21111019 | 0.82 | MMP2 (0.36) | POLBL3MBTL1 | |
| SCHEMBL20973171 | 0.82 | ATM (0.40) | ATMPIK3CDDPP4DPP8DPP9 | |
| SCHEMBL15819175 | 0.82 | ATM (0.40) | ATMPIK3CDDPP4DPP8DPP9 | |
| SCHEMBL18720347 | 0.82 | ATM (0.53) | ATMPOLBL3MBTL1PIK3CDDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11548888-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2023-01-10 | — | — | US | disclosed |
| CN-114805311-A | Spirocyclic indenes | 苏州亚盛药业有限公司 | 2022-07-29 | — | — | CN | disclosed |
| US-20200331911-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2020-10-22 | — | — | US | disclosed |
| US-6372736-B1 | ENZYME INHIBITORS | PFIZER INC | 2002-04-16 | — | — | US | disclosed |
| EP-1100797-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ROTAMASE ENZYMES | Pfizer Limited (GB) | 2001-05-23 | — | — | EP | disclosed |
| WO-2000005232-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ROTAMASE ENZYMES | PFIZER LIMITED (GB) | 2000-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11548888-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | ATM 3528/4885POLB 1699/4885L3MBTL1 2112/4885 |
| US-20200331911-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | ATM 3528/4885POLB 1699/4885L3MBTL1 2112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.